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Abstract
The enzyme-linked immunosorbent spot (ELISpot) assay is one of the most commonly used
methods to measure antigen-specific T cells in both mice and humans. Some of the primary
reasons for the popularity of the method are that ELISpot is highly quantitative, can measure a
broad range of magnitudes of response and is capable of assessing critical cellular immune-related
activities such as IFN-γ secretion and granzyme B release. Furthermore, ELISpot is adaptable not
only to the evaluation of a variety of T-cell functions, but also to B cells and innate immune cells.
It is no wonder that ELISpot has evolved from a research tool to a clinical assay. Recent Phase I
and II studies of cancer vaccines, tested in a variety of malignancies, have suggested that ELISpot
may be a useful biomarker assay to predict clinical benefit after therapeutic immune modulation.
This article will discuss the most common applications of ELISpot, overview the efforts that have
been undertaken to standardize the assay and apply the method in the analysis of human clinical
trials, and describe some important steps in the process of developing a clinical-grade ELISpot.
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The first description of the enzyme-linked immunosorbent spot (ELISpot) assay was
published over 25 years ago [1]. Since then, ELISpot has become one of the most commonly
used immunoassays in the evaluation of human clinical trials of vaccines and other forms of
immunotherapy. Indeed, the number of publications using ELISpot methodology has
increased exponentially since that first report. We searched PubMed online for the keyword
‘ELISpot’ and downloaded all available citations as of early December 2010 (Figure 1). The
first year with a publication citing ‘ELISpot’ per se was 1983, and since then the number of
publications has gone up dramatically to 288 publications in 2005 and remains high.
Originally, ELISpot was developed as an alternative to the hemolytic plaque [2] and the
protein A plaque assay [3]. The ELISpot assay differed from the older techniques by
omitting the use of conjugated red blood cells and replacing them with a stable plastic
surface on which antigens were adhered. The spatial separation of the antigen-specific cells
and the use of a visible spot to enumerate the cells allowed for improved quantitation of
antibody-secreting cells.
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Over the last two decades, a number of protocol enhancements have been published,
beginning with the ‘reverse’ ELISpot technique (RELISpot). Adhering antibodies instead of
antigens to the solid-phase surface reversed the protocol to detect secreted antigens instead
of secreted antibodies. The introduction of nitrocellulose membranes and epitope-specific
monoclonal antibodies allowed the ‘reverse’ detection of secreted IFN-γ, which resulted in
the ELISpot assay being increasingly applied to the study of vaccine-induced responses
[4,5]. Commercially available antibodies, 96-well nitrocellulose plates and, later,
polyvinylidene fluoride plates, further enhanced the performance and high-throughput
capabilities of the ELISpot assay. Indeed the adaptability of the assay to multiple platforms
is a major reason for its popularity today (Box 1).
Box 1
Advantages of enzyme-linked immunosorbent spot assay
• Platform is adaptable to multiple cell types (e.g., T cells and B cells) as well as
to multiple secreted products (e.g., cytokines and granzyme B)
• Can be standardized across multiple laboratories
• Quantitative
• Measures cell function, which may be a predictor of outcome after
immunotherapy
• Lower limit of detection than flow-based immunoassays
• Inexpensive
There are additional reasons for the rapid adoption of the assay as a workhorse in clinical
immunologic monitoring (Box 1). Since the technique is similar to ELISA and western
blotting, troubleshooting assay development uses methods familiar to most laboratory
personnel. The assay has a lower limit of detection than immunoassays dependent on flow
cytometric techniques. Moreover, the ELISpot provides not only a quantitative but also a
functional readout for therapy-induced immune responses. Since ELISpot has been shown to
be standardizable across laboratories and the method can be performed without expensive
instrumentation, ELISpot has been used as a primary assay in clinical trials performed in
developing countries. It should be noted, however, that the advent of the ELISpot reader has
added to the standardization of the assay for clinical use as well as to the cost of the assay.
This article will outline the most common research and clinical applications of ELISpot,
overview the efforts that have been ongoing in the standardization of the assay and, finally,
provide information concerning some of the elements needed within a laboratory to execute
ELISpot at a level suitable for clinical trials.
Common ELISpot adaptions for immune monitoring
IFN-γ ELISpot
Although the ELISpot assay was initially developed to detect antibody-secreting cells [1], it
has been widely used to evaluate both CD4+ and CD8+ T cells responding to an antigenic or
mitogenic stimulus [6,7]. Among the various types of ELISpot, the IFN-γ-based assay is the
most common application of the technique [8,9].
IFN-γ is an abundant cytokine produced by Th1 cells and is frequently used to track specific
CD8+ responses. As many different cytokines, including other Th1 cytokines (such as IL-2
and TNF-α) and also Th2 cytokines (such as IL-15 and IL-13) are produced by a smaller
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proportion of antigen-specific T cells, the use of ELISpot for these cytokines is often limited
[10]. While IFN-γ-secreting antigen-specific T cells can be detected directly from the
peripheral blood, detection of other types of cytokine-secreting cells may require an in vitro
expansion step to augment low-level responses. The advent of the semi- or fully automated
plate readers markedly increased the sensitivity and reproducibility of the IFN-γ ELISpot
assay. Indeed, a lower limit detection threshold of less than 25 IFN-γ-producing T cells per
million in peripheral blood mononuclear cells (PBMCs) has been reported [11].
The additional in vitro stimulation technique is specific to unmasking lower level responses
as it has been shown to enhance the magnitude of IFN-γ ELISpot responses to
cytomegalovirus peptides in serologically positive patients without generating false positive
responses in serologically negative patients. The elicitation of these responses was 100%
specific [12].
The IFN-γ ELISpot assay has been used extensively for the screening of immune responses
in the development of vaccines for the prevention and treatment of many kinds of diseases
including AIDS, malaria and TB [13,14]. While ELISpot responses to infectious disease
antigens are easily detected, there has not been a strong correlation of IFN-γ-secreting cells
and disease protection or pathogen-specific antibody responses [15,16]. It may be that the
high baseline levels of immunity in patients with infectious disease preclude association of
cellular immunity with disease progression or regression. Alternatively, clinically effective
viral-specific immune responses may require the detection of more than a single type of
cytokine-producing T cell. A modification of the IFN-γ ELISpot, which assesses the
proliferative potential of IFN-γ-secreting cells by adding a culture step with peptide, has
been shown to expand antigen-specific memory cells and may improve the correlative
power of ELISpot in monitoring HIV treatment. Investigators demonstrated an inverse
correlation of viremia with levels of HIV-specific memory T cells identified in this manner
as well as a direct correlation of CD4+ counts with the ELISpot detected IFN-γ-secreting
HIV-specific memory cells [17]. Of note, IFN-γ ELISpot responses were recently shown to
correlate with resolution of vulvar intraepithelial neoplasia after the administration of a
peptide-based human papillomavirus-specific vaccine (p = 0.02) [18].
Data have suggested that IFN-γ ELISpot responses induced by cancer vaccines may
correlate with disease outcome. Clinical trials have shown a significant correlation of
antigen-specific ELISpot responses with survival after a melanoma antigen-specific peptide-
based vaccine in advanced-stage patients [19]. Moreover, the magnitude of antigen-specific
IFN-γ-secreting cells, as measured by ELISpot, trended towards survival after the
administration of a prostate-specific antigen vaccine in prostate cancer patients (p = 0.06)
[20], as well as a human epidermal growth factor receptor 2 (HER2/neu) specific vaccine in
breast cancer patients (p = 0.08) [21]. One of the major problems with attempting to define a
correlation of clinical response with immune response as assessed by ELISpot is that, first,
clinical responses generally occur in a minority of patients and, second, the clinical trials are
grossly underpowered for a biomarker correlation to these responses. Unfortunately, larger
randomized clinical trials, for the most part, do not include performance of ELISpot
analysis. Larger studies with greater numbers of patients matched with appropriate controls
will be needed to validate ELISpot or any other immunologic marker as a correlate to a
clinical response.
Granzyme B ELISpot
One of the mechanisms of cell cytotoxicity involves the release of cytoplasmic granular
proteins, including the pore-forming protein, perforin, and a family of serine proteases called
granzymes, for example, granzyme B. Granzyme B is secreted mainly from CD8+ cytotoxic
lymphocytes and natural killer cells and may induce the killing of virus-infected and tumor
Slota et al. Page 3
Expert Rev Vaccines. Author manuscript; available in PMC 2012 May 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
cells [22–25]. The detection of granzyme B-secreting cells via ELISpot is well established
and previous studies have reported that granzyme B ELISpot has excellent correlation with
the 51Cr-release assay for measuring cytotoxic activity of effector cells including cytotoxic
lymphocytes and natural killer cells [26–28]. Compared to the IFN-γ ELISpot assay, the
granzyme B ELISpot may be a more direct measure of cytotoxic cell activity because
granzyme B is one of the primary molecules in effector cell-mediated killing.
TGF-β1 ELISpot
TGF-β plays an important role in tumor initiation and progression, functioning as both a
suppressor and a promoter and also regulating infiltration of inflammatory/immune cells and
cancer-associated fibroblasts in the tumor microenvironment. Development of an ELISpot
assay for TGF-β1 was initially difficult as the majority of TGF-β1 was produced by
mononuclear cells in the latent form. Recently, however, reagents have become available,
such as TGF-β1 soluble receptor type II and antibodies to TGF-β1 that specifically
recognize active TGF-β1 [29]. Investigators have reported that there was significant
correlation between the frequency of TGF-β1-producing cells as measured by ELISpot and
total secreted TGF-β1 as measured by ELISA in patients infected with Mycobacterium
avium [30]. It has been suggested that TGF-β1 ELISpot assays are 100–200-fold more
sensitive than ELISA in the detection of the cytokines from whole-cell secretions [31,32].
Fluorescent ELISpot
Fluorescent ELISpot assays using fluorophore-labeled detection antibodies have been shown
to perform similarly to immuno-enzymatic ELISpots [33]. Moreover, using fluorescent-
labeled capture antibodies allows detection of multiple cytokine production from the same
cell. Careful optimization must be carried out to ensure that cross-reactivity between
anticytokine antibodies is eliminated and that results from the multiple-cytokine assay are
consistent with single-color assays done in the same experiment. A specialized plate reader
is required for fluorospot assays [33].
Additional cytokines detectable using an ELISpot platform
Many other cytokines (IL-1β, -2, -4, -6, -8, -10, -12 and -17, and TNF-α) and chemokines
have been evaluated by ELISpot assay in preclinical and clinical studies. ELISpot kits
assessing these cytokines are now, for the most part, commercially available [34–38].
Recent approaches have combined the detection of two or more different cytokines
simultaneously in a multicolor ELISpot with reproducible results leading to an increased
range of detectable responses as well as the differentiation of the quality of the response.
Some complicating factors in the use of the multicolor ELISpot are the necessity for greater
amounts of cells per well, the increase in assay duration, and the potential decrease in
sensitivity of the assay when multiple colors are used [38], although in some cases these
have not been shown to limit the use of the assay. Other limiting factors may be the
difficulty in discriminating dual-stained spots, the technical challenges involved in obtaining
similarly defined spots for both cytokines and, in the case of the IL-2/IFN-γ dual-color
assay, overcoming IL-2 dependence for IFN-γ secretion. Some of these limitations may be
surmounted by choosing the fluorospot assay as the mode of analysis, but this assay is not
without its own limitations as described previously.
Detecting polyfunctional T cells
Polyfunctional T cells may be important in mediating disease control [38]. In HIV trials in
particular, single-color ELISpot assays were used along with intracellular cytokine staining
to detect IL-2, IFN-γ and TNF-α, and when combined with limiting dilution assays to detect
cytotoxic T-cell precursor frequency, polyfunctional T cells were shown to have increased
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following treatment. By using the generation of polyfunctional T cells as a marker for
effective vaccination, investigators demonstrated a negative correlation between effective
vaccination and HIV viral load, although as the patients in this study were also using
antiretroviral therapy, the clinical effect of vaccination remains unclear [39]. The assessment
of polyfunctional T cells is typically done using flow cytometry-based assays such as
intracellular cytokine staining, and has been correlated with vaccination in different settings
[40]. Assessing polyfunctional T cells by ELISpot to detect multiple cytokines may improve
the correlation of immunological monitoring assays with clinical response and allow the
evaluation of effective vaccination.
Translation of ELISpot from a research to a clinical tool
As stated earlier, ELISpot is a sensitive assay that can detect a low frequency of antigen-
specific T cells; however, the multiple steps comprising the assay can lead to high variation
and imprecision if the method is not validated. A variety of factors impact the performance
characteristics of ELISpot; these include: cell recovery and viability, operator technique and
proficiency, the different vendors and lots of reagents, experimental protocols used for assay
execution, protein additives in media, manual or automated spot enumeration and data
analysis.
One of the most critical steps in standardizing ELISpot is to ensure adequate cell recovery
and viability after rescuing PBMCs from cryopreservation. This issue is particularly
important depending on what cell populations are being used for the assay. If unfractionated
PBMCs are used for ELISpot, the method of cryopreservation could impact the function of
endogenous antigen-presenting cells thus decreasing T-cell activity. If T cells are to be
purified prior to analysis, the method of cryopreservation could significantly impact the
recovery of viable cells. As the purification process consumes many cells, fewer viable cells
available for purification may mean that assays cannot be performed as designed. The adult
AIDS Clinical Trials program demonstrated that retaining a cell viability of 70% or greater
after thawing was associated with maintenance of functional responses [41]. Our group has
reported that viability after thawing was significantly negatively impacted by the use of
human AB serum in the cryopreservation media (p < 0.001) and the temperature of the cells
after the thaw. Reconstituting the cells in media that was chilled to 4°C reduced viability by
nearly 30% as compared with media warmed to 37°C [42]. ELISpot can be optimized for
serum-free conditions as well [43]. A comparative study, performed at multiple different
sites, using serum-free or serum-containing media, demonstrated no significant difference in
the number of viable cells retrieved, the background of the assay or the ability to detect
antigen-specific responses between the two types of media [43,44].
Once assay issues have been standardized, ELISpot has been shown to have a significant
correlation with T-cell responses measured by another method, such as cytokine flow
cytometry, in the same samples [45]. Comparative analyses have demonstrated that ELISpot
has a higher coefficient of variation (CV) for intra-assay precision and inter-operator
precision compared with flow cytometric-based assays such as MHC tetramer and cytokine
flow cytometry [46]. Standardization of ELISpot around common validated protocols is
necessary for the clinical application of the method to immunotherapy trials. In order to
establish the feasibility of the assay to precisely monitor human vaccine clinical trials, the
reproducibility of ELISpot in multiple laboratories has been studied in several proficiency
panels. ELISpot assays can provide reproducible results among different laboratories when
the assay procedure and data analysis are standardized [47,48]. With good laboratory
practice and standard operating procedures (SOPs), an interlaboratory CV for the frequency
of antigen-specific T cells was found to be less than 20% [49]. Other proficiency panel
studies have shown that strict adherence to protocols that detail cell handling, ELISpot
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execution and plate reading can greatly improve the quality of the data generated by a poorly
performing laboratory [50]. In particular, the issue of high assay background may be
addressed through careful reagent choice [51], optimized sample processing and handling
[45,52], a standard method of assay optimization using the same specimen set to ensure
consistent results [51], and additional optimization strategies [53]. The choice of antigen-
presenting cell used also affects background levels and ELISpot results [51].
There has been much discussion of how to define the ‘response to vaccination’ using the
ELISpot assay. As mentioned previously, in clinical trials of both infectious disease and
cancer vaccines, subjects frequently enter the study with significant detectable levels of
antigen-specific T cells, as measured by ELISpot, prior to receiving the immune-based
intervention. In many clinical trials, owing to the small number of patients enrolled and the
limited number of samples, the data are not normally distributed and a Student’s T-test
method is not suitable for defining positive response [54]. Different standards have been
proposed to define positive responses induced by vaccines, such as fourfolds of negative
control [55], and >50 spots per 106 PBMC [49]. In cancer vaccine trials, an additional
criterion that is commonly used is the mean and two standard deviations (SDs) of pre-
existing tumor antigen-specific T-cell responses; measuring a value greater than this
criterion post-vaccination may be used to define whether a vaccine increased antigen-
specific INF-γ-secreting cells [21], as two SDs is equivalent to a p-value of 0.05 [56]. A
recent report has analyzed various statistical methods on a single sample set and has shown
the strengths and weaknesses of different statistical approaches. The authors suggest the use
of a nonparametric statistical test to define augmentation of an immune response as
measured by IFN-γ ELISpot [54].
There are multiple published tools available to the user for the standardization and analysis
of ELISpot assays. While reproducible data can be achieved with the adaptation of these
tools, other issues need to be addressed in the development of a clinical laboratory that can
maintain and track quality performance of the ELISpot over time.
Maintaining the quality performance of ELISpot
In addition to simply developing a SOP for the execution of ELISpot, other steps must be
taken to ensure that not only does the assay perform as expected initially, but that it
continues to perform to clinical standards over time. A documented training protocol,
reagent validation, a readily available biorepository of normal and cancer donors, and
regular quality assurance reporting and data analysis are all crucial parts of immune
monitoring programs that maintain quality ELISpot performance. Many laboratories do not
have the qualified personnel or the volume of assays necessary to make an investment in
developing a quality program for ELISpot. However, there are many resources available,
both at academic medical centers as well as in the private sector, for the contracting of
clinical-grade ELISpot assays.
Laboratory training
A comprehensive training program covers both general institutional training as well as
assay-specific training and includes performance standards. In the case of ELISpot, we find
proficiency training requires a longer time to complete as compared with more automated
assays (e.g., ELISA) as the ELISpot requires a higher level of technical proficiency. In
general, for assay performance, the new or re-certifying employee observes the assay
performed by an experienced technician with a validated technique. After observing the
assay, the new employee will perform the assay under close supervision and step-by-step
guidance from an experienced technician. The assay will be repeated under close
supervision until the results and reproducibility of the assay fall within acceptable laboratory
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values of known standards. At that point, precision, accuracy and intra- and inter-assay
variability should be assessed across a larger number of samples to ensure the new
employee’s assay performance characteristics are in accordance with the rest of the
laboratory.
In our Immunologic Monitoring Core Laboratory, samples that have been previously
characterized for CMV responses and are derived from our repository are used for training.
If the repeated results fall within the assay validation standards, the new employee is
considered fully trained and allowed to perform clinical assays unsupervised. The plate
controls (CMV-positive samples) for the new employee are monitored weekly during their
probationary period for deviations. All plate controls on a study are trended monthly, and all
employees must perform proficiency testing quarterly to maintain assay validation
standards.
Training documentation
Laboratory training documentation is managed centrally to ensure compliance with federal,
state and local health, safety and security regulations as well as job-specific requirements.
An audit of individual employee training should be performed annually, and employees
should be certified during the first 6 months of employment, re-certified at their 1-year
employment anniversary, and reviewed at least annually thereafter. Each laboratory
employee should complete SOP training when the SOPs are initially established as well as
when they are modified. All original training data should be kept on file for review by
laboratory supervisors and regulators. Ensuring that all assays performed in the laboratory
are done by qualified technicians who can achieve comparable results is essential to a
successful immune monitoring program.
Reagent validation
Prior to beginning a clinical trial, all reagents should be tested to ensure that assays
performed using those reagents perform at historical standards. All efforts must be made to
ensure that clinical trials can be completed with as few reagent lot changes as possible by
ordering particular lot numbers in bulk. If new reagents are added during the conduct of a
trial, a defined reference population must be used to compare the old, validated reagent with
the new reagent to be introduced. Assay performance must conform to the standards set in
order for the new reagent to be introduced into the study. Reagent validation reports should
summarize the performance comparison between old and new reagents. Tagging data with
reagent lot numbers in an experimental data management database simplifies this process.
Performance standards
All assays should include controls: typically, ELISpot assays include a ‘no antigen’ control
in which the cells are plated in the media of choice, a positive control such as
phytohemagglutinin (PHA) or phorbol myristate acetate (PMA), and a negative control,
which can be an irrelevant antigen or a media-only well, preferably both if available cell
number allows. A positive control sample should be run on each plate to track inter-assay
variability as discussed previously. Because ELISpot is a sensitive assay with a relatively
large detection range, it is also important to define different response levels. Variation of the
assay often differs with different level of responses so assay validation must include
assessments at the low, medium and high range of assay performance. Adherence to quality
standards must be maintained across the full range of detectable responses.
Prior to assay use in a clinical trial, we refine the assays to the specific antigen system and
establish performance characteristics. To define the normal range of response, we use
PBMCs from 20 normal donors derived from our biorepository. This population is also used
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as our reference population for qualifying lots of reagents as discussed previously. In
addition, these donors will be earmarked for plate controls and ongoing quality assurance
throughout the course of the study. We evaluate these 20 donors for responses to our
standard set of positive and negative controls as well as the antigens specific to the trial. No-
antigen and media-only wells are used as background controls and CMV, Epstein–Barr virus
and influenza virus (CEF) peptide mix, and PHA are positive controls. Assays are performed
in six to eight well replicates. Once the assay is standardized, we also evaluate ten cancer
patient samples to determine if there is a pre-existing response to the antigen. This data is
helpful in providing methods to determine what is positive versus negative during the course
of a trial. The definition of response in normal controls allows assessment of the sensitivity
and specificity of the assay for the intervention. A leukapheresis program for collection and
storage of control populations is critical for maintaining assay performance.
Continuing assay performance reporting
Frequent quality assurance monitoring such as monthly performance reports includes the
standard positive and negative control results for every assay run that month. Average
values and SDs are compared with historical results, and CV for all assays must remain
within laboratory standard values. Deviation will trigger an investigation and further sample
analysis will be halted until the problem is identified, documented and corrected. The
control data are trended monthly to insure inter- and intra-assay performance. In addition,
results of no-antigen wells along with mitogen controls should be trended to ensure each
assay is performing within limits. Positive no-antigen wells and negative mitogen wells are
commonly used as prospectively defined criteria for assay exclusion. If at any point the
monthly or quarterly reports show assay performance that does not conform to the standards
set, troubleshooting and assay testing is required to determine the source of the issue and to
bring the assay back to standard.
These are just a few of the issues that should be considered when preparing to develop
ELISpot as an immunologic monitoring tool for the assessment of human clinical trials of
immune-based interventions. Further issues are addressed in recent publications assessing
results across multiple institutions [57].
Expert commentary
The ELISpot assay is functional, highly quantitative, and has a large range of detection. This
makes the assay suitable to a wide variety of clinical applications. ELISpot can assess
cytokine release from antigen-specific cells as well as cytokine secretion from activated
innate immune cells. The ability of the assay to be adapted to measure the response of
multiple different cell types to a stimulus has made ELISpot an important tool in monitoring
human immunity.
Although ELISpot is a cell-based assay, multiple studies have demonstrated that ELISpot
can be perfected to meet rigorous performance standards. Multiple excellent SOPs are
available for the conduct of ELISpot and reagents are available to expand the capability of
the assays to assess different effector functions and even simultaneous secretion of a variety
of cytokines from single cells.
Thus, ELISpot may not only provide a potency assay to assess the ability of a vaccine to
induce an immune response, but also a biomarker of vaccine efficacy. Clinical trials should
be designed to attempt to validate ELISpot as a biomarker of clinical response after immune
intervention.
Slota et al. Page 8
Expert Rev Vaccines. Author manuscript; available in PMC 2012 May 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Five-year view
With the advent of several immune-based therapies appearing to have beneficial clinical
effects, especially in cancer patients, the ability to monitor the immune response stimulated
by those therapies will be critical. Assays will have to be simple, inexpensive and highly
accurate to be able to be adapted to pivotal Phase III clinical trials. Evaluating the
remarkable evolution of ELISpot from its origins into the immune monitoring tool that it has
become today, there is no doubt there will be future modifications of the assay that further
simplify and expand its capabilities. ELISpot remains a tool that can assess a large variety of
immune effectors as well as the multiple functions of those effectors. Validation of ELISpot
as a potential immunologic biomarker assay with prognostic significance would ensure
ongoing adaptation of the assay as a primary mode for measuring human immunity in
clinical trials.
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Key issues
• Enzyme-linked immunosorbent spot (ELISpot) is a highly flexible assay and can
be adapted to multiple readout formats.
• ELISpot assays are quantitative and measure key cellular functions of immune
system cells.
• ELISpot has been used to assess both adaptive and innate immune responses.
• The ELISpot assay can be standardized across multiple laboratories using
common standard operating procedures, which have resulted in the translation
of the assay from the laboratory to a clinical tool.
• Preliminary data in cancer immunotherapy trials suggests that the magnitude of
the ELISpot response may be associated with treatment-related clinical benefit.
• Adaptation of ELISpot to clinical use requires development of a quality program
as well as rigorous tracking of assay performance characteristics.
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Figure 1. Frequency of publications citing ELISpot
Data were collected from a PubMed search for the keyword ‘ELISpot’. Publication dates
were sorted by year and a histogram showing frequency of publications per year was
generated using the XML code for date of publication. The figure was last updated in early
December 2010.
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